Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis.

Next Previous
X
Search
Trial Profile

A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cibinetide (Primary)
  • Indications Neuropathic pain; Sarcoidosis
  • Focus Therapeutic Use
  • Acronyms DOSARA
  • Sponsors Araim Pharmaceuticals

    • Most Recent Events

    • 08 May 2017 Results published in an Araim Pharmaceuticals media release.
    • 08 May 2017 Primary endpoint (Change in Corneal Nerve Fiber Area) has been met, according to an Araim Pharmaceuticals media release.
    • 05 Jul 2016 According to the Araim Pharmaceuticals media release, the US Food and Drug Administration (FDA) and the EU has granted Orphan Drug Designation to Cibinetide (ARA 290) for the treatment of sarcoidosis. Also, it has received a Fast Track designations from USFDA for the treatment of neuropathic pain in patients with sarcoidosis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top